Research and analysis

ACMD advice on consumer cannabidiol (CBD) products

Report from the Advisory Council on the Misuse of Drugs (ACMD) on consumer cannabidiol (CBD) products.

Documents

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The ministerial commission asked the ACMD to specify which controlled cannabinoids should be controlled and set an unavoidable trace level for each of these within consumer CBD products.

Updates to this page

Published 17 December 2021
Last updated 24 October 2023 show all updates
  1. The government鈥檚 response to the ACMD鈥檚 advice has been added.

  2. Added HTML accessible version of documents.

  3. First published.

Sign up for emails or print this page